Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Children's Hospital, Translational Genomics Research Institute, and University of Arizona.
"Be the change you wish to see in the world..." Gandhi
ANGEL’S STORY - as told by Angel's mother
On May 4, 2018 Angel Carden was like any ordinary 8 year old boy. He was just finishing up 3rd grade and enjoying the last days of Little League Baseball. After a day on the baseball field, Angel started to have seizures later on that night. We rushed him to an emergency room and a CT scan discovered that Angel had a large tumor growing in the back of his brain. Our world felt like it was ending, we were scared, and we desperately feared for our son’s dear life.
Angel was immediately transferred by ambulance to Phoenix Children’s Hospital, only one of a few places in the country that could properly care for our son. By the time we were admitted the tumor was causing increased pressure to his brain. This caused Angel to continuously vomit, barely speak, unable to move and started to lose his vision. Angel’s neurosurgeon Dr. Ruth Bristol was the one to diagnose our son with Stage 4 Medulloblastoma. She let us know that he had to immediately have surgery for 2 shunts, to relieve the pressure on his brain before any permanent damage was done. We spent 14 days in the Pediatric Intense Care Unit and Angel’s final surgery lasted over 7 hours to remove his brain tumor.
We prayed so much during that time, and had started to meet so many new people that cared for our son as much as we did. After the surgery Angel could barely move or talk, which is common with posterior fossa syndrome. When we left the hospital at the end of May, Angel was in a wheelchair and his Dad had to lift him into our car to take him home. Every day I watch my son defy the odds against him. He went to physical, speech, and occupational therapy; exceeded every goal they set for him in the span of 4 months. Since then Angel has went on to complete Proton Radiation Therapy as Scottsdale Mayo Clinic under Dr. Sameer Keole for about 8 weeks. He now walks, talks, and went from writing with his left hand to right hand. Angel is even going to school when he feels up to it. Angel just wanted to share his story to never give up, and he wants to give back for every child that may be going through the same circumstance that Angel has been through.
PLEASE SUPPORT SSBTR to help Angel and the far too many like him!
“One of the great movements in my lifetime among educated people is the need to commit themselves to action. Most people are not satisfied with giving money; we also feel we need to work.”
— Peter Drucker
Report analyses the Brain Tumor Diagnosis And Therapeutics market By Type, By Applicatio, assesses the market By Region (Europe, Asia Pacific, North America, Rest of the world) and By Country (United Kingdom, Germany, U.S., Canada, Mexico, Japan, India, France, China, Australia), assesses the market for the historical period of 2014-2018 and the forecast period of 2019-2024.
A new drug, known as IP1867B, could be used for future treatments of brain tumors. The research team showed that IP1867B worked with existing cancer treatments boosting their effectiveness and, in some cases, restored sensitivity to some treatments.
Forrest General became the first hospital in Mississippi to use Gleolan™ (aminolevulinic acid HCl) for enhanced visualization of high-grade gliomas (including glioblastomas), or tumors occurring in the glial cells of the brain. This solution causes tumor cells to glow red under blue light allowing the neurosurgeon to remove as much of the tumor as possible without affecting healthy brain cells.
An international team led by researchers has discovered the energy production mechanism of cancerous cells that drives the growth of the nucleolus and causes tumors to rapidly multiply. The findings could lead to the development of new cancer treatments that would stop tumor growth by cutting the energy supply to the nucleolus.
Massachusetts General Hospital (MGH) investigators have created a new method that could make immune therapy more effective again brain tumors and expand its use against other types of solid tumors.
The Ivy Brain Tumor Center at the Barrow Neurological Institute, has released the results of its recent Phase 0 clinical trial of the breast cancer drug ribociclib (Kisqali®) for the treatment of recurrent glioblastoma. The agent, recently approved by the FDA for advanced breast cancer, is part of a newly-discovered class of targeted therapy that undermines cancer cell division and could form the backbone of a new drug cocktail for patients with malignant brain tumors like glioblastoma.
